Table V.

Mechanism of action of the antipsychotic and antidepressant drugs included

Drug names	Mechanism of action
Aripiprazole	Unknown. The efficacy could be mediated through a combination of partial agonism at dopamine type 2 receptors and serotonin 5-HT1A receptor and antagonist activity at 5-HT2A receptor.
Duloxetine	Unknown. The mechanisms of the antidepressant, central pain inhibitory and anxiolytic actions of are believed to be related to its potentiation of serotoninergic and noradrenergic activity in the central nervous system
Paliperidone	Unknown. The efficacy in schizophrenia has been proposed to be mediated through a combination of central dopamine type 2 and serotonin 5-HT2A receptor antagonism.
Lurasidone	Unknown. The efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine type 2 receptor and serotonin 5-HT2A receptor antagonism.
Escitalopram	The mechanism is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from its inhibition of central nervous system reuptake of serotonin (5-HT).
Risperidone	Unknown. The mechanism could be mediated through a combination of antagonism of dopamine type 2 receptor and serotonin 5-HT2 receptor.
Asenapine	Unknown. The efficacy in schizophrenia could be mediated through a combination of antagonism of 5-HT2A and D2 receptors
Quetiapine	Unknown. The efficacy in schizophrenia could be mediated through a combination of dopamine type 2 receptor and serotonin 5-HT2A receptor.
Olanzapine/fluoxetine	Unknown. The mechanism has been proposed that the activation of 3 monoaminergic neural systems (serotonin, norepinephrine, and dopamine) is responsible for its enhanced antidepressant effect.
Olanzapine	Unknown. The mechanism has been proposed that this drug’s efficacy in schizophrenia is mediated through a
	combination of antagonism at dopamine type 2 receptor and serotonin 5-HT2A receptor.